1-[4-(2,4-difluoro-benzyloxy)-phenyl]-ethanone

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-[4-(2,4-difluoro-benzyloxy)-phenyl]-ethanone
• 英文别名: 1-(4-((2,4-difluorobenzyl)oxy)phenyl)ethanone；1-(4-(2,4-difluorobenzyloxy)phenyl)ethanone；4-(2,4-difluorobenzyloxy)acetophenone；1-[4-[(2,4-Difluorophenyl)methoxy]phenyl]ethanone
• 化学式: C₁₅H₁₂F₂O₂
• mdl: MFCD17040704
• 分子量: 262.256
• InChiKey: XKYBANCIZAYIRX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.133
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-[4-(2,4-difluoro-benzyloxy)-phenyl]-ethanone 在 溶剂黄146 作用下， 以 乙醇 为溶剂， 反应 25.0h， 生成 4-methyl-piperazine-1-carbothioic acid {1-[4-(2,4-difluoro-benzyloxy)-phenyl]-ethylidene}hydrazide
  参考文献：
  名称：

  [EN] BENZOTHIOPHENE, BENZYLOXYBENZYLIDENE AND INDOLINE DERIVATIVES USEFUL FOR THE TREATMENT OF TUBERCULOSIS
  [FR] BENZOTHIOPHÈNE, BENZYLOXYBENZYLIDÈNE ET DÉRIVÉS DE L'INDOLINE UTILES POUR LE TRAITEMENT DE LA TUBERCULOSE

  摘要：

  本发明涉及苯并噻吩、苄氧基苯甲醛亚甲基和吲哚啉-2-酮衍生物，以及该衍生物在结核病的治疗和/或预防中的应用。

  公开号：

  WO2016041972A1
• 作为产物：
  描述：

  2,4-二氟溴苄 、 对羟基苯乙酮 在 potassium carbonate 、 potassium iodide 作用下， 以 丙酮 为溶剂， 反应 24.0h， 以87%的产率得到1-[4-(2,4-difluoro-benzyloxy)-phenyl]-ethanone
  参考文献：
  名称：

  [EN] BENZOTHIOPHENE, BENZYLOXYBENZYLIDENE AND INDOLINE DERIVATIVES USEFUL FOR THE TREATMENT OF TUBERCULOSIS
  [FR] BENZOTHIOPHÈNE, BENZYLOXYBENZYLIDÈNE ET DÉRIVÉS DE L'INDOLINE UTILES POUR LE TRAITEMENT DE LA TUBERCULOSE

  摘要：

  本发明涉及苯并噻吩、苄氧基苯甲醛亚甲基和吲哚啉-2-酮衍生物，以及该衍生物在结核病的治疗和/或预防中的应用。

  公开号：

  WO2016041972A1

文献信息

• Compounds for the treatment of metabolic disorders
  申请人：——

  公开号：US20030149107A1

  公开（公告）日：2003-08-07

  Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.

  适用于治疗各种代谢性疾病的化合物，如胰岛素抵抗综合征、糖尿病、高脂血症、脂肪肝病、虚弱、肥胖、动脉粥样硬化和动脉硬化的化合物已被披露。
• Acetophenone derivatives: novel and potent small molecule inhibitors of monoamine oxidase B
  作者：Zhi-Min Wang、Xue-Mei Li、Wei Xu、Fan Li、Jin Wang、Ling-Yi Kong、Xiao-Bing Wang

  DOI：10.1039/c5md00357a

  日期：——

  series of acetophenone derivatives have been designed, synthesized and evaluated for human monoamine oxidase A and B inhibitory activity in vitro. Most of the tested compounds acted preferentially on MAO-B with IC50 values in the nanomolar range and weak or no inhibition of MAO-A. In particular, compounds 1j (IC50 = 12.9 nM) and 2e (IC50 = 11.7 nM) were the most potent MAO-B inhibitors being 2.76- and 2

  已经设计，合成和评估了两个系列的苯乙酮衍生物在体外对人单胺氧化酶A和B的抑制活性。大多数测试的化合物优先以30纳摩尔范围的IC 50值对MAO-B起作用，对MAO-A的抑制作用弱或无抑制作用。特别是化合物1j（IC 50 = 12.9 nM）和2e（IC 50= 11.7 nM）是最有效的MAO-B抑制剂，其活性比司来吉兰高2.76倍和2.99倍。此外，MAO-B抑制的结构-活性关系表明，苯乙酮部分C3和C4处的取代基，特别是被卤素取代的苄氧基取代，对MAO-B抑制更有利。已经进行了分子对接和动力学研究以解释MAO-B与苯乙酮衍生物的结合模式。此外，代表性化合物1j和2e在SH-SY5Y细胞中显示出低神经毒性。可以得出结论，苯乙酮衍生物可用于开发有望用于治疗神经退行性疾病的先导化合物。
• Compound for the treatment of metabolic disorders
  申请人：Sharma Shalini

  公开号：US20050090555A1

  公开（公告）日：2005-04-28

  Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.

  本发明涉及一种用于治疗各种代谢障碍的化合物，如胰岛素抵抗综合症、糖尿病、高脂血症、脂肪肝病、消瘦、肥胖症、动脉粥样硬化和动脉硬化等。
• COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
  申请人：Sharma Shalini

  公开号：US20070105958A1

  公开（公告）日：2007-05-10

  Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.

  本发明揭示了一些化合物，用于治疗各种代谢性疾病，如胰岛素抵抗综合征、糖尿病、高脂血症、脂肪肝病、消瘦、肥胖症、动脉粥样硬化和动脉硬化等。
• Novel aryloxy azolyl chalcones with potent activity against Mycobacterium tuberculosis H37Rv
  作者：Vijay K. Marrapu、Vinita Chaturvedi、Shubhra Singh、Shyam Singh、Sudhir Sinha、Kalpana Bhandari

  DOI：10.1016/j.ejmech.2011.06.037

  日期：2011.9

  A series of twenty seven novel aryloxy azolyl chalcones were synthesized and evaluated in vitro for the growth inhibition of Mycobacterium tuberculosis H37Rv. Ten compounds from this series exhibited good activity with MIC in the range of 3.12-0.78 mu g/mL and six of them were found non-toxic against VERO cells and MBMDMos (mouse bone-marrow derived macrophages), were further evaluated ex-vivo for their potential to kill intracellular bacilli. Two compounds 4 and 19 showed 99% and 71% killing respectively, of intracellular bacilli in MBMDMos infection model. Further, compound 19, an imidazolyl chalcone with a 2,4-difluorobenzyloxy moiety also exhibited moderate in vivo activity in mice against virulent M. tuberculosis, thus providing a new structural lead towards TB drug development. (C) 2011 Elsevier Masson SAS. All rights reserved.